Nautilus Biotechnology

Nautilus Biotechnology, Inc. operates as a life sciences company. The firm develops proteomics platform for analyzing and quantifying the human proteome. The company was founded by Sujal Patel and Parag Mallick in 2016 and is headquartered in Seattle, WA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nautilus Biotechnology reports strong financials and strategic collaborations

Nautilus Biotechnology is strategically positioned with strong financials and key collaborations for future growth.
The company's focus on innovation and customer engagement sets the stage for a successful commercial launch in mid-2024.
Despite challenges like increasing expenses and supply chain issues, Nautilus is poised to capitalize on market opportunities.
CEO's vision of a highly differentiated product and market evolution aligns with the company's strategic direction.

Nautilus Biotechnology advances towards proteome access, strong financial position

Nautilus Biotechnology's Q1 2023 performance reflects strong advancements in its scientific and engineering objectives, positioning the company well for its upcoming platform launch in mid-2024. With a robust financial position and a focus on strategic investments, Nautilus is poised for long-term growth and innovation in the proteomics market.

Nautilus Biotechnology advances in proteomics with strong financial backing

Nautilus Biotechnology's Q2 performance reflects steady progress towards developing a groundbreaking proteomic platform, supported by active industry engagement and a strong financial position.
While facing challenges in managing operating expenses and executing on its technological vision, the company's strategic strengths and opportunities position it for future success.
With a clear focus on innovation and customer value, Nautilus is well-equipped to drive growth, deliver on its promises, and shape the future of proteomics.

Nautilus Biotechnology progresses in Q3, eyes market revolution and growth

Nautilus Biotechnology's Q3 performance reflects advancements in R&D, financial stability, and strategic partnerships.
The company's strengths lie in its innovative platform, expert team, and confidence in value proposition.
Challenges include competitive positioning, operational hurdles, and managing expenses effectively.
Opportunities for Nautilus Biotechnology include industry engagements, market penetration, and sustainable growth.

Nautilus Biotechnology advances Proteome Analysis Platform launch to 2025

Nautilus Biotechnology made progress in 2023 towards launching the Proteome Analysis Platform in 2025, despite a net loss of $17.0 million in Q4. The company's focus on scalability, reproducibility, and collaborations with key partners positions it well for future growth. Challenges in refining the platform's quality and milestones in protein decoding are being addressed to maximize long-term value.

Nautilus Biotechnology excels in proteomics, faces inquiries and growth

Nautilus Biotechnology demonstrated strong performance in proteomic data analysis and platform development in Q1 2024.
While facing challenges in addressing analyst inquiries and managing financial aspects, the company remains well-positioned.
Opportunities lie in leveraging positive feedback, advancing platform development, and engaging in global events for growth.

Nautilus Biotechnology progresses towards commercial launch amidst financial stability

Nautilus Biotechnology demonstrated strong performance and financial stability in Q2 2024, positioning itself for future growth and commercial success.
The company's focus on proteoforms, technological advancements, and strategic leadership are key strengths driving its competitive edge.
Challenges in meeting timelines, managing costs, securing funding, and navigating market competition require strategic focus and execution.
Opportunities in the growing proteomics market, technology advancements, partnerships, and market expansion offer avenues for future growth and success.

Nautilus Biotechnology reports robust Q3 performance and eyes market expansion

Nautilus Biotechnology's Q3 2024 earnings call highlighted strong financial performance, platform development progress, and strategic leadership appointments.
The company's focus on efficient cash management, extended cash runway, and future growth plans underscore a commitment to long-term success.
While facing challenges in probe development and commercialization, Nautilus Biotechnology is well-positioned to capitalize on opportunities in partnerships and market expansion.
Overall, Nautilus Biotechnology's emphasis on innovation, financial prudence, and market engagement sets a positive trajectory for future growth and industry impact.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nautilus Biotechnology, Inc. is a life sciences company, which engages in the development of a proteomics platform for analyzing and quantifying the human proteome. Its products include Proteome Analysis System, Reagent Kits, and Software and Analysis. The company was founded by Sujal Patel and Parag Mallick in 2016 and is headquartered in Seattle, WA.

SEATTLE, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2021.

Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2021 Financial Results

SEATTLE, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating virtually in the upcoming 42nd Annual Cowen Health Care Conference.

Nautilus to Participate in the 42nd Annual Cowen Health Care Conference

Nautilus operates in the field of Proteomics, a $25 billion market, growing at 12% per year.

Nautilus Biotechnology: Recent Selloff Provides A Fantastic Entry Point

Ardelyx

Cumberland Pharma

Petros Pharmaceuticals

Are these on your list of penny stocks to buy this week? The post Penny Stocks To Buy This Week: 4 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy This Week: 4 To Watch Right Now

Nautilus Biotechnology, Inc. (NAUT) CEO Sujal Patel on Q3 2021 Results - Earnings Call Transcript

Abcam

SEATTLE and CAMBRIDGE, England, Nov. 2, 2021 /PRNewswire/ -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, and Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences research tools, today announced a strategic development and supply partnership. The relationship leverages Abcam's industry-leading recombinant monoclonal antibody development technologies and expertise to enhance Nautilus' reagent research and development, and establishes a long-term supply relationship between the companies.

Nautilus and Abcam Announce Strategic Partnership to Accelerate Exploration of the Proteome

SEATTLE, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today reported financial results for the third quarter ended September 30, 2021.

Nautilus Biotechnology Reports Third Quarter 2021 Financial Results

SEATTLE, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the third quarter of fiscal year 2021 before market open on Tuesday, November 2nd, 2021.

Nautilus Biotechnology to Announce Third Quarter of Fiscal Year 2021 Financial Results on November 2, 2021

SEATTLE, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, today announced the company will be participating virtually in the upcoming Morgan Stanley Global Healthcare Conference.

Nautilus to Participate in the Morgan Stanley Global Healthcare Conference

Nautilus Biotechnology seeks to deliver on the untapped potential of the human proteome.

Nautilus Biotechnology: Tapping The Potential Of The Human Proteome

Nautilus Biotechnology's (NAUT) CEO Sujal Patel on Q2 2021 Results - Earnings Call Transcript

SEATTLE, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome, today reported financial results for the second quarter ended June 30, 2021.

Nautilus Biotechnology Reports Second Quarter 2021 Financial Results

Former Pacific Biosciences executive brings deep expertise in single-molecule analysis to large-scale platform designed to comprehensively quantify the proteome Former Pacific Biosciences executive brings deep expertise in single-molecule analysis to large-scale platform designed to comprehensively quantify the proteome

Nautilus Biotechnology Appoints Karl Voss, Ph.D., as Vice President of Life Sciences Research and Development

Nautilus Biotechnology Inc (NASDAQ: NAUT) shares are trading higher during mid-day trading on Thursday following a CNBC report that Amazon.com Inc (NASDAQ: AMZN) held around $15 million stake in the company at the end of Q2. The $14.7 million investment was disclosed in a recent Amazon SEC Form 13F filing.

Why Nautilus Biotechnology (NAUT) Stock Trading Higher Thursday?

Nautilus is developing a platform that works to measure and identify the complexities of proteins, which could lead to drug discoveries.

Nautilus Biotechnology soars 65% after Amazon reveals a $15 million stake in the small-cap company

Amazon

Shares of Nautilus Biotechnology rose by as much as 50% on Thursday morning after a report revealed that Amazon has taken an equity stake in the newly public Seattle-based company.

Nautilus Biotechnology shares surge 50% on news of Amazon investment

Amazon declined to specify whether it's working with Nautilus Technology in addition to investing. The online retailer has been pushing into health care.

Amazon invested millions in a pre-revenue company with a system for measuring human proteins

SEATTLE, July 13, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the second quarter of fiscal year 2021 before market open on Tuesday, August 10th, 2021.

Nautilus Biotechnology to Announce Second Quarter of Fiscal Year 2021 Financial Results on August 10, 2021

Nautilus Biotechnology is emerging as Seattle's newest publicly traded company this week, taking advantage of the mania over SPACs to raise $345 million to fuel a new approach that could accelerate biomedical research and transform drug development.

Sujal Patel-led Nautilus Biotechnology goes public as it tackles ambitious plan to analyze proteins

SEATTLE and NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the completion of its business combination with Arya Sciences Acquisition Corp III (Nasdaq: ARYA; or “Arya III”), a special purpose acquisition company (SPAC) sponsored by Perceptive Advisors. The combined company, Nautilus Biotechnology, Inc. (“Nautilus”), will commence trading shares of its common stock under the ticker symbol “NAUT” on the Nasdaq Global Select Market on June 10, 2021.

News for Nautilus Biotechnology Stock (NAUT)